US · Healthcare · Drug Manufacturers - General
EPS came in at 2.46 against a street estimate of 2.25 — a beat of 9.3%.
Analysts rate Novartis AG ADR a hold (5 buy, 5 hold, 2 sell out of 12) with an average price target of $154.80.
| Fund | Stake |
|---|---|
| Fisher Asset Management, LLC | 0.82% |
| Morgan Stanley - Brokerage Accounts | 0.46% |
| Dimensional Fund Advisors, Inc. | 0.43% |
| PRIMECAP Management Company | 0.35% |
| Loomis, Sayles & Company LP | 0.28% |
| Bank of America Corp | 0.26% |
| Franklin Templeton Inc | 0.17% |
| BlackRock Inc | 0.16% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Q3 2026 net sales were USD 14.5 billion, up 4% in both reported and constant currencies. Nine-month sales were USD 42.0 billion, u | 2026-10-27 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Novartis reported that the Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 (DM1) did not meet its primary endpo | 2026-09-08 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint. • The trial tested whe | 2026-09-04 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Novartis reported positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple | 2026-09-01 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 net sales were USD 14 408 million, up 3% in reported currency and 1% at constant currencies. H1 sales were USD 27 521 mill | 2026-07-21 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Novartis AG filed its Form 20-F annual report for the fiscal year ended December 31, 2025, on February 4, 2026. • The company pre | 2026-02-04 |
| Annual report FY2024 (20-F) | 2025-01-31 |
| Annual report FY2023 (20-F) | 2024-01-31 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $4.77 / share ex-date Mar 11, 2026 · pay Mar 16, 2026 | 2026-03-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Novartis AG ADR — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.